PTPRC and neoplasm: MC38 tumors treated with A12-VHHkappa-DM4 contained few live cells and had fewer CD11b+CD45+ myeloid cells (Fig. 6D), suggesting that A12-VHH kappa-DM4 increased the depletion of tumor-associated macrophages.